Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | KDR | P35968 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.63 |
| ▸ | TUBB | P07437 | 6/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.63 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.63 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.63 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035998 | 0.88 | LMNA (0.54) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL31197292 | 0.86 | LMNA (0.82) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL31197291 | 0.86 | LMNA (0.82) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL11402164 | 0.85 | TUBB4A (0.76) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL30700091 | 0.85 | LMNA (0.64) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL5345719 | 0.85 | LMNA (0.65) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL28601663 | 0.84 | LMNA (0.63) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL5351444 | 0.84 | LMNA (0.63) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL11171725 | 0.84 | LMNA (0.63) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL6126460 | 0.84 | LMNA (0.63) | LMNACYP1A2HIF1ASMN1; SMN2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | LMNA 4225/4885CYP1A2 734/4885HIF1A 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.